Recent advances in cancer immunotherapy using monoclonal antibodies have dramatically
revolutionized the therapeutic strategy against advanced malignancies, inspiring the …

Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …

Despite considerable advances in the treatment of multiple myeloma (MM) in the last
decade, a substantial proportion of patients do not respond to current therapies or have a …

Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …

Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only
a fraction of patients with cancer responds to immunotherapy, and currently available …

The immune-cell origin of hematologic malignancies provides a unique avenue for the
understanding of both the mechanisms of immune responsiveness and immune escape …

T cells in the immune system protect the human body from infection by pathogens and clear
mutant cells through specific recognition by T cell receptors (TCRs). Cancer immunotherapy …

Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies
have become the largest class of biopharmaceuticals with over 80 antibodies currently …

Bispecific antibodies (bsAbs) refer to a large family of molecules that recognize two different
epitopes or antigens. Although a series of challenges, especially immunogenicity and chain …

The redirection of T cells against tumors holds much promise for the treatment of cancer.
Two main approaches for T-cell redirection involve their genetic modification with chimeric …